Treatment protocol
[대역어] 치료 프로토콜
[용어속성] Term
[용어속성] Term
A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
Research Article
[키워드] addition
adjusted
age
anticoagulation
approach
average
Chi squared test
collected
COVID-19 pandemic
COVID-19 patient
decrease
died
Evidence
FIVE
Gender
Healthcare system
Hospitalization
ICU
Immune-mediated
implementation
in-hospital mortality
intensive care
Intervention
Logistic regression
LOS
material
mechanical ventilation
mechanism
medication
Mortality
mortality rate
Observational cohort study
older patient
outcome
Oxygenation
Patient
patients treated
reduce
reduction in
Result
rising
severe COVID-19
severe COVID-19 patient
Standard-of-care
stratified
the United State
treated
Treatment
treatment group
Treatment protocol
was performed
was reduced
were measured
[DOI] 10.1371/journal.pone.0245025 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0245025 PMC 바로가기 [Article Type] Research Article
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial
COVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hours
7-point ordinal scale
acute respiratory distress
acute respiratory distress syndrome
Administered
administration
Admission
Adult patient
Adult patients
Adverse
Adverse drug reactions
AEs
age
All trial participants
all-cause mortality
allergy
Allogeneic
ARDS
assessment
assigned
baseline
Biomarker
blinded
Blinding
C-reactive protein
carcinoma
carcinoma in situ
carried
cellular
chain
change
childbearing potential
Chloroquine
Clinical practice
clinical status
clinical trial
coagulation test
coagulation tests
conducted
Control
control arm
Course
COVID
COVID-19
CRF
criteria
CT scan
cumulative incidence
current
Cytokines
D-dimer
Day
death
described
determined by
Diagnosis
disease
dissemination
double-blind
drug
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
End
endpoints
enrolment
EudraCT
evaluate
evaluate the effect
event
exclusion criteria
Extracorporeal
extracorporeal membrane oxygenation
failure
ferritin
fibrosis
FiO2
form
GRADE
grade 3
greater
Haemodialysis
handling
hemofiltration
history
hospital
Hospitalization
hydroxy
ICU
ICU admission
IMPROVE
include
inclusion criteria
Informed consent
intravenous
Intravenous administration
intravenous dose
intubation
Invasive mechanical ventilation
invasive ventilation
investigational medicinal product
involved
laboratory confirmation
laboratory-confirmed SARS-CoV-2 infection
lactation
LDH
less
Level
Local
Lopinavir
Lopinavir/ritonavir
lung disorder
lymphocyte
marker
Mechanical
mechanical ventilation
Medicine
Medicines
Mesenchymal stromal cells
moderate to severe
Mortality
MSC
negative pregnancy test
neoplasm
neutrophil
neutrophil counts
Non-invasive
number
objective
occur
off-label
opinion
Ordinal Scale
organ
oropharyngeal swab
oropharyngeal swabs
Other
outcome
oxygen
oxygen saturation
Oxygen therapy
PaO2
PaO2/FiO2 ratio
parameters
participant
Patient
PCR
percentage
Placebo
polymerase chain reaction
Pregnancy
primary endpoint
product
Production
profile
progression
protocol
Pulmonary embolism
pulmonary fibrosis
Pulmonary function tests
randomised
randomised controlled trial
randomization
Randomized
Randomly
Rapid antigen tests
reaction
receive
recruitment
Registered
Remdesivir
report
respiratory
Respiratory distress syndrome
Resuscitation
Ritonavir
SAEs
Sample size
SARS-COV-2 infection
secondary
Secondary endpoints
Sequential Organ Failure Assessment
Serious Adverse Events
SOFA
Spain
specificity
specimen
Sponsor
Standard of care
status
stromal cell
stromal cells
Study protocol
subpopulations
supplemental oxygen
supplementary material
syndrome
the cell
the disease
the patient
the primary endpoint
the WHO
time
Tocilizumab
Tolerability
Treatment
treatment arm
treatment for COVID-19
treatment group
Treatment protocol
Trial
trial participant
Trial registration
unit
website
women
worldwide pandemic
written consent
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
Influence of aluminum salts on COVID-19 infected patients
COVID-19 감염 환자에 대한 알루미늄 염의 영향
Observational Study
[키워드] addition
alum
aluminum
aluminum salts
Analysis
Antiviral
Chain Reaction
clinical
Clinical findings
Comorbidity
Control
control group
Coronavirus (COVID-19)
COVID-19
COVID-19 infected patient
COVID-19 infected patients
CRP level
CRP levels
diagnosed
discharge
drop
Effect
examined
Follow-up
group
Hospital stay
Hospitalization
include
infected cases
infected patients
Infectious disease
influence
intake
intensive care
Laboratory parameters
Lactate
lactate dehydrogenase
LDH
material
mechanical ventilation
not achieved
oral intake
pandemic
patients
PCR
performed
Pneumonia
polymerase chain
polymerase chain reaction
procalcitonin
procalcitonin level
radiological
Recovery time
recovery times
Result
retrospective cohort study
salt
salts
Side effect
Side effects
significantly
significantly shorter
survival
Symptom
Symptoms
the patient
Toxicity
Treatment
treatment group
Treatment protocol
treatment protocols
two group
two groups
[DOI] 10.3906/sag-2009-140 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.3906/sag-2009-140 PMC 바로가기 [Article Type] Observational Study
Comparison of the clinical manifestations between different age groups of patients with overseas imported COVID-19
Research Article
[키워드] Abnormalities
Admission
Adverse drug reaction
age
antiviral therapy
Beijing
Chest CT
clinical manifestation
Clinical practice
clinical symptom
Clinical symptoms
Comorbidity
complications
condition
courses
COVID-19
COVID-19 patient
COVID-19 patients
demographic data
disease
disease onset
epidemiological history
faster
greater
group
Hospital stay
Hospitalization
IgG
IgM
Increased
investigated
lab
lung involvement
multiple lesion
nucleic acid
Occurrence
outcome
outcomes
Patient
proportion
risk
significantly
significantly more
the disease
the patient
Treatment protocol
two group
type 2 diabete
type 2 diabetes
[DOI] 10.1371/journal.pone.0243347 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0243347 PMC 바로가기 [Article Type] Research Article
Gynecological cancers and the global COVID-19 pandemic
Review
[키워드] Affect
Asymptomatic
CA-125
Cancer
cancers
Cervical
Chemotherapy
Chest
Computerized tomography
concerning
contrast medium
coronavirus
COVID-19
COVID-19 pandemic
database
debate
detect
diagnosed
Diagnosis
early stage
Elective surgery
Endometrial Cancer
Guidance
gynecological cancer
Health
lesion
lung lesions
management
Middle East
oncology
outpatient clinic
ovarian
ovarian cancer
Patient
performed
Pregnancy
Radiotherapy
recommendation
reduced
resource
respiratory
searched
serum
stages
suction
the patient
therapy
treated
Treatment
treatment approach
Treatment protocol
vaginal cancer
vegetation
women
[DOI] 10.4274/jtgga.galenos.2020.2020.0119 PMC 바로가기 [Article Type] Review
[DOI] 10.4274/jtgga.galenos.2020.2020.0119 PMC 바로가기 [Article Type] Review
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
하이드록시클로로퀸 + 아타자나비르/리토나비르 치료 후 중등도 및 중증 COVID-19로 입원한 환자의 결과 비교
Comparative Study
[키워드] 28-day mortality
Admission
adverse events
age
Antiviral
antiviral therapy
Atazanavir
atazanavir/ritonavir
baseline
Clinical outcome
clinical outcomes
Complication
Course
COVID-19
Definition
discharge
discharge rate
discharged patient
discharged patients
disease
Dyspnea
Efficacy and safety
evaluated
exertional dyspnea
Hair loss
hospital
Hospital admission
hospital discharge
Hospital stay
Hospitalization
hospitalized patient
Hydroxychloroquine
ICU
incidence
intensive care
intensive care unit
intubation
investigated
Length
less
male
matter
moderate
Mortality
National
national treatment
outcome
outcomes
oxygen
Patient
patients
patients treated
patients with COVID-19
patients with moderate
peripheral oxygen saturation
Pneumonia
regimen
Ritonavir
Serious Adverse Event
Serious Adverse Events
severe COVID-19
severe disease
severe group
severity
significantly higher
significantly shorter
SpO2
Support
Symptom
the disease
the patient
Treatment
treatment of COVID-19
Treatment protocol
use of hydroxychloroquine
weakness
WHO definition
[DOI] 10.1007/s40199-020-00369-2 PMC 바로가기 [Article Type] Comparative Study
[DOI] 10.1007/s40199-020-00369-2 PMC 바로가기 [Article Type] Comparative Study
SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study
의료 종사자의 SARS-CoV-2 항체 유병률: 단일 센터 연구의 예비 보고서
Research Article
[키워드] adaptive
addition
adjusted
age
Analysis
antibody
blood sample
Care
Cell mediated immunity
Cohort
collected
Community
Complete
conducted
COVID-19 antibody
COVID-19 symptoms
cross-reactive
described
Fever
General population
greater
Health
healthcare
healthcare worker
Healthcare workers
higher risk
hospital
household contact
household contacts
IgG antibodies
IgG antibody
implementation
include
increasingly
independent
individuals
Infection
Infection transmission
initial
investigated
Local
Loss of Smell
mediated immunity
medical staff
Observed
orange
outcomes
patient triage
PCR test
Personal protective equipment
positive
Prevalence
recruited
risk
SARS-CoV-2
SARS-CoV-2 antibody
Sensitivity and specificity
serological survey
Serological surveys
serum analysis
Significant
single center
subject
T cell
tested
Travel
Treatment protocol
was collected
with COVID-19
[DOI] 10.1371/journal.pone.0240006 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0240006 PMC 바로가기 [Article Type] Research Article
Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope
Review
[키워드] acute respiratory syndrome
Antithrombotic
approved
Care
caused
clinical investigation
clinical trial
confirmed case
coronavirus
Coronavirus-2
Corticosteroids
COVID-19
current
effective
Effective therapies
global pandemic
Health
Healthcare system
highlight
Human
immunoglobulins
immunotherapies
Infectious disease
intravenous
knowledge
Laboratory
less
life-threatening
nocturnal
Oxygen therapy
pandemic
plasma
potential therapy
Radiotherapy
Research
Safety
SARS-CoV-2
therapeutic
Therapeutic approach
therapeutic option
Therapies
Treatment
Treatment protocol
Vaccine
Vaccines
virus
[DOI] 10.1016/j.intimp.2020.107156 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.intimp.2020.107156 PMC 바로가기 [Article Type] Review
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] adjuvant
Administered
Adverse
age
alanine aminotransferase
All study participant
allergy
approved
ARDS
Aspartate transaminase
Aspirin
atorvastatin
benefit
bleeding
block randomization
Breastfeeding
C-reactive protein
characterized
clinical
Clinical deterioration
Clinical improvement
Clinical outcome
Coagulopathy
collected data
computer-generated
conducted
confirmed case
control group
COVID-19
COVID-19 patient
COVID-19 patients
CPK
creatine phosphokinase
Critical
derivative
discharge
dissemination
dose
drug
drug interaction
ECMO
Effect
element
Endotracheal intubation
enrolment
ethical committee
evaluated
examined
excluded
exclusion criteria
Final
Hepatitis
HIV
Hospital admission
hospital discharge
hospitalisation
ICMR
ICU admission
in-hospital mortality
include
Inclusion
India
infected with SARS-CoV-2
Inflammatory marker
interim analysis
liver
management
mechanical ventilation
Medical Science
medication
Mortality
myalgia
National Cancer Institute
New
Non-invasive
number
objective
Open-label
Other
outbreak
outcome
outcomes
pandemic
parallel-group
participant
Patient
patients
Platelet
Pregnancy
Primary outcome
progression
Protease inhibitor
protease inhibitors
protocol
randomised
Randomised control trial
randomised controlled trial
randomize
Randomized
receiving
recruited
recruitment
reference
Registered
registry
renal replacement therapy
respiratory
RT-PCR
Sample size
SARS-CoV-2
SARS-COV-2 infection
secondary outcome
serum
Shock
statin
status
study period
Study protocol
supplementary material
symptom onset
Tablet
therapy
Treatment protocol
Trial
troponin
usual care
website
WHO
written consent
written Informed Consent
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter